Prediction and prevention of type 1 diabetes: Progress, problems, and prospects

Clinical Pharmacology and Therapeutics

Volumn 81, Issue 5, 2007, Pages 768-771

  Skyler, J S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; GLUCOSE;

ARTICLE; CELL FUNCTION; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; IMMUNE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESPONSE; PANCREAS ISLET CELL TUMOR; PREDICTION; PRIORITY JOURNAL; PROPHYLAXIS;

DIABETES MELLITUS, TYPE 1; FATTY ACIDS, OMEGA-3; FEMALE; FORECASTING; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOTHERAPY; INFANT, NEWBORN; INSULIN; NIACINAMIDE; PREGNANCY;

EID: 34247264408     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100179     Document Type: Article

References (45)

1. Atkinson, M. & Eisenbarth, G. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358, 221-229 (2001).
2. Devendra, D., Liu, E. & Eisenbarth, G.S. Type 1 diabetes: recent developments. BMJ 328, 750-754 (2004).
3. Bonifacio, E. et al. Quantification of islet-cell antibodies and prediction of insulin-dependent diabetes. Lancet 335, 147-149 (1990).
4. Riley, W.J. et al. A prospective study of the development of diabetes in relatives of patients with insulin-dependent diabetes. N. Engl. J. Med. 323, 1167-1172 (1990).
5. Verge, C.F. et al. Prediction of type I diabetes in first-degree relatives using a combination of insulin GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 45, 926-933 (1996).
6. Eisenbarth, G.S. Prediction of type 1 diabetes: the natural history of the prediabetic period. Adv. Exp. Med. Biol. 552, 268-290 (2004).
7. Bingley, P.J. Interactions of age, islet cell antibodies, insulin autoantibodies, and first-phase insulin response in predicting risk of progression to IDDM in ICA+ relatives: The ICARUS data set. Diabetes 45, 1720-1728 (1996).
8. Chase, H.P., et al. & The Diabetes Prevention Trial- Type 1 Study Group First phase insulin release during the intravenous glucose tolerance test as a risk factor for type 1 diabetes. J. Pediatr. 138, 244-249 (2001).
9. Sosenko, J.M., et al. & The Diabetes Prevention Trial- Type 1 Study Group Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 29, 643-649 (2006).
10. Bingley, P.J. et al. Can islet cell antibodies predict IDDM in the general population? Diabetes Care 16, 45-50 (1993).
11. Schatz, D. et al. Islet cell antibodies predict insulin-dependent diabetes in United States school age children as powerfully as in unaffected relatives. J. Clin. Invest. 93, 2403-2407 (1994).
12. Pugliese, A. et al. HLA-DQB1*0602 is associated with dominant protection from diabetes even among islet cell antibody-positive first-degree relatives of patients with IDDM. Diabetes 44, 608-613 (1995).
13. Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N. Engl. J. Med. 346, 1685-1691 (2002).
14. Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of oral insulin in relatives of patients with type 1 diabetes mellitus. Diabetes Care 28, 1068-1076 (2005).
15. Rewers, M. et al. Beta-cell autoantibodies in infants and toddlers without IDDM relatives: Diabetes Autoimmunity Study in the Young (DAISY). J. Autoimmun. 9, 405-410 (1996).
16. Schenker, M. et al. Early expression and high prevalence of islet autoantibodies for DR3/4 heterozygous and DR4/4 homozygous offspring of parents with Type I diabetes: the German BABYDIAB study. Diabetologia 42, 671-677 (1999).
17. Achenbach, P., Bonifacio, E., Koczwara, K. & Ziegler, A.G. Natural history of type 1 diabetes. Diabetes 54(Suppl 2): S25-S31 (2005).
18. Sherry, N.A., Tsai, E.B. & Herold, K.C. Natural history of β-cell function in type 1 diabetes. Diabetes 54(Suppl 2): S32-S39 (2005).
19. Skyler, J.S. & Marks, J.B. Immune intervention in type 1 diabetes mellitus. Diabetes Rev. 1, 15-42 (1993).
20. Slover, R.H. & Eisenbarth, G.S. Prevention of type I diabetes and recurrent-cell destruction of transplanted islets. Endocr. Rev. 18, 241-258 (1997).
21. Schatz, D.A., Krischer, J.P. & Skyler, J.S. Now is the time to prevent type 1 diabetes. J Clin. Endocrinol. Metab. 85, 495-498 (1999).
22. Kolb, H. & Gale, E.A. Does partial preservation of residual beta-cell function justify immune intervention in recent onset Type I diabetes? Diabetologia 44, 1349-1353 (2001).
23. Feutren, G., et al. & for the Cyclosporin/Diabetes French Study Group. Cyclosporin increases the rate and length of remissions in insulin dependent diabetes of recent onset: results of a multicentre double-blind trial. Lancet ii, 119-124 (1986).
24. The Canadian-European Randomized Control Trial Group. Cyclosporin-induced remission of IDDM after early intervention: association of 1 year of cyclosporin treatment with enhanced insulin secretion. Diabetes 37, 1574-1582 (1988).
25. Skyler, J.S., Rabinovitch, A. & Miami Cyclosporine Diabetes Study Group. Cyclosporine in recent onset type 1 diabetes mellitus: effects on islet beta cell function. J. Diabetes Complicat. 6, 77-88 (1992).
26. Harrison, L.C., Colman, P.G., Dean, B., Baxter, R. & Martin, F.I.R. Increase in remission rate in newly diagnosed type 1 diabetic subjects treated with Azathioprine. Diabetes 34, 1306-1308 (1985).
27. Silverstein, J., Maclaren, N., Riley, W., Spillar, R., Radjenovic, D. & Johnson, S. Immunosuppression with Azathioprine and Prednisone in recent onset insulin-dependent diabetes mellitus. N. Engl. J. Med. 319, 599-604 (1988).
28. Cook, J.J. et al. A double-blind controled trial of Azathioprine in children with newly-diagnosed type 1 diabetes. Diabetes 38, 779-783 (1989).
29. De Filippo, G., Carel, J.C., Boitard, C. & Bougnères, P.F. Long-term results of early cyclosporin therapy in juvenile IDDM. Diabetes 45, 101-104 (1996).
30. Parving, H.H. et al. Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study. Diabetes Care 22, 478-483 (1999).
31. Gotfredsen, G.F., Buschard, K. & Frandsen, E.K. Reduction of diabetes incidence of BB Wistar rats by early prophylactic insulin treatment of diabetes-prone animals. Diabetologia 28, 933-935 (1985).
32. Like, A.A. Insulin injections prevent diabetes (DB) in BioBreeding/Worcester (BB/W) rats. Diabetes 136, 3254-3258 (1986).
33. Atkinson, M.A., Maclaren, N.K. & Luchetta, R. Insulitis and insulin dependent diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 39, 933-937 (1990).
34. Keller, R.J., Eisenbarth, G.S. & Jackson, R.A. Insulin prophylaxis in individuals at high risk of type 1 diabetes. Lancet 341, 927-928 (1993).
35. Füchtenbusch, M., Rabl, W., Grassl, B., Bachmann, W., Standl, E. & Ziegler, A.G. Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial. Diabetologia 41, 536-541 (1998).
36. Weiner, H.L. Oral tolerance for the treatment of autoimmune diseases. Annu. Rev. Med. 48, 341-351 (1997).
37. Zhong, Z.J., Davidson, L., Eisenbarth, G.S. & Weiner, H.L. Suppression of diabetes in non obese diabetic mice by oral administration of porcine insulin. Proc. Natl. Acad. Sci. USA 88, 10252-10256 (1991).
38. Bergerot, I., Fabien, N., Maguer, V & Thivolet, C. Oral administration of human insulin to NOD mice generates CD4+ T cells that suppress adoptive transfer of diabetes. J. Autoimmun. 7, 655-663 (1994).
39. von Herrath, M.G., Dyrberg, T. & Oldstone, M.B. Oral insulin treatment suppresses virus-induced antigen-specific destruction of beta cells and prevents autoimmune diabetes in transgenic mice. J. Clin. Invest. 98, 1324-1331 (1996).
40. European Nicotinamide Diabetes Intervention Trial (ENDIT). European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 363, 925-931 (2004).
41. Paronen, J. et al. Effect of cow's milk exposure and maternal type 1 diabetes on cellular and humoral immunization to dietary insulin in infants at genetic risk for type 1 diabetes. Finnish Trial to Reduce IDDM in the Genetically at Risk Study Group. Diabetes 49, 1657-1665 (2000).
42. Raz, I., Elias, D., Avron, A., Tamir, M., Metzger, M. & Cohen, I.R. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 358, 1749-1753 (2001).
43. Agardh, C.D. et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J. Diabetes Complicat. 19, 238-246 (2005).
44. Herold, K.C. et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346, 1692-1698 (2002).
45. Keymeulen, B. et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 352, 2598-2608 (2005).